Ampio Pharmaceuticals Announces Agreement to Acquire Key Drug Delivery Technology
News Dec 06, 2011
The Zertane™ ODT formulation allows for rapid oral absorption, ease of use without the need for liquids and avoids unpleasant bitter taste. This acquisition provides additional intellectual property to protect Zertane™ ODT's unique formulation, over and above the many method of use claims for Zertane™ contained in patents Ampio already owns. The Company indicated that acquisition of the rights to this technology is expected to speed and facilitate Ampio's filing of marketing authorization applications for product regulatory approvals of Zertane™ worldwide and is important for the additional planned licensing and pricing agreements currently in negotiations. The completion of the transaction is subject to customary conditions, including a certain third party consent and successful completion of a technology and materials transfer plan more fully described in a Form 8-K to be filed shortly.
"This acquisition of this technology is an important step in the manufacturing and commercialization plan for Zertane™. This agreement demonstrates our commitment to the fast and successful launch of a unique dosage and formulation of Zertane™. The Zertane™ commercialization plan is on course as outlined in the previous press releases and securities filings. We are committed to complete the development of a combination product of Zertane™ with a PDE5 inhibitor to simultaneously treat both premature ejaculation and erectile dysfunction. Our strategy with this line of products is to expeditiously pursue multiple licensing partners worldwide." stated Don Wingerter, Ampio's CEO.
New Partnership to Provide Bioanalytical and DMPK ServicesNews
Concept Life Sciences, the integrated drug discovery, development and analytical services company, and Alderley Analytical, bioanalytical Contract Research Organisation (CRO), today announced they have signed a partnership agreement to provide high-value bioanalytical and DMPK study services.
PPD and Quotient Sciences Form Innovative Partnership to Accelerate Pediatric Drug DevelopmentNews
Will shorten timelines, reduce costs and simplify contracting process in pediatric programs.READ MORE